In Section A, contributors will obtain unique doses and schedules of oral ABBV-744 pill to recognize safe dosing regimen. More members will probably be enrolled for the discovered monotherapy dosign regimen. In Section B, members will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Section C, https://abbv-744-cancer-treatment91245.fare-blog.com/32078836/5-simple-statements-about-abbv-744-clinical-trial-phase-1-results-explained